

12 May 2016

ASX Code: MXC

## Priority Offer Timetable - Update

**MGC Pharmaceuticals Limited** (ASX: MXC or “the Company”) would like to confirm the Priority Offer (PO) Prospectus for shareholders is proceeding on schedule for lodgement on Monday 16 May 2016.

The timetable is detailed below for the PO and will be confirmed in the Prospectus once issued.

Record Date	5.00pm(WST) 13 May 2016
Lodgement of Prospectus with the ASIC and ASX	16 May 2016
Lodgement of Appendix 3B	16 May 2016
Opening Date	16 May 2016
Closing Date*	25 May 2016
Expected date of Official Quotation of the Securities*	26 May 2016

\*The Directors reserve the right to alter these dates without notice.

Key items of the PO include:

- The PO will be placed on a first come first served basis
- The PO will be open to all shareholders who hold shares at 5.00pm (WST) on 13 May 2016 (Record Date)
- The PO Prospectus will be posted to shareholders with their Entitlement Form however shareholders who would like to download their Entitlement Form for faster acceptance will be able to login to Computershare’s Investor Centre on or around 17 May 2016. A link to Computershare’s Investor Centre is [here](#)
- Each eligible shareholder will be able to apply for set allocations of \$2,500, \$5,000, \$10,000 or \$15,000 under the PO

-Ends-

**For further information, please contact:**

**Media Enquiries**

Andrew Ramadge  
Senior Account Manager  
Media and Capital Partners  
+61 475 797 471  
[andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 9389 2000  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**About MXC**

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing European cosmetics and medical markets.